Showing results (51-60 of 224) with videos related to

Sort By:
Pageof 23
Expert Opinion on Biological Therapy|October 25, 2021
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanomaMohammad Fazel, Neda AlRawashdh, Ahmad Alamer, et al.
Clinical Therapeutics|February 24, 2015
Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation studyDiana Sun, Tri Murti Andayani, Ahmed Altyar, et al.
The International Journal of Risk & Safety in Medicine|July 9, 2019
Why health policies should be transnational: A case for East Asia Pacific countriesPreshit Nemdas Ambade, Chinmayee Katragadda, Diana Sun, et al.
Journal of Managed Care & Specialty Pharmacy|March 25, 2022
Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United StatesNeda Alrawashdh, Ali McBride, Marion Slack, et al.
Future Oncology (London, England)|September 6, 2017
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzAli McBride, Sanjeev Balu, Kim Campbell, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 17, 2023
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatmentMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
Future Oncology (London, England)|July 9, 2021
Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapyAli McBride, Neda Alrawashdh, Trace Bartels, et al.
Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 24, 2023
The economic value of knowing BRCA status: <i>BRCA</i> testing for optimizing treatment in recurrent epithelial ovarian cancerMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
International Journal of Nursing Studies|December 3, 2005
Work environment and workforce problems: a cross-sectional questionnaire survey of hospital nurses in BelgiumKoen Milisen, Ivo Abraham, Kaat Siebens, et al.
Pageof 23